RAB33B

Across TCGA pan-cancer cohorts, RAB33B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RAB33B data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB33B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RAB33B expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where RAB33B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	1.000	0.928	.013	19	view →
CCRCC	OS	Median	III,IV	0.881	0.680	.009	8	view →
LUAD	OS	Quartile	All	0.756	0.948	.010	8	view →
PDAC	DFS	Median	All	0.701	0.892	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RAB33B–HNSC (OS)

Open the HNSC breakdown →